Prime Capital Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Prime Capital Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$81.5K	Sell	26,547 -1,355	-5%	-$5.24K	﹤0.01%	1011
2025 Q4	$114K	Buy	27,902 +499	+2%	+$2.47K	﹤0.01%	985
2025 Q3	$134K	Sell	27,403 -2,943	-10%	-$15.5K	﹤0.01%	962
2025 Q2	$154K	Buy	30,346 +11,492	+61%	+$56.5K	﹤0.01%	911
2025 Q1	$99.7K	Buy	18,854 +7,381	+64%	+$53.8K	﹤0.01%	1007
2024 Q4	$77.6K	Buy	11,473 +1,306	+13%	+$8.78K	﹤0.01%	902
2024 Q3	$67K	Sell	10,167 -11	-0.1%	-$79	﹤0.01%	895
2024 Q2	$76.3K	Buy	+10,178	New	+$88.8K	﹤0.01%	893

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prime Capital Investment Advisors's RXRX Position: Q1 2026 in Review

Prime Capital Investment Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 4.9% in Q1 2026, selling an estimated $5.24K and leaving 26,547 shares worth $81.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1011.

Prime Capital Investment Advisors first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $154K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Prime Capital Investment Advisors held 26,547 shares of Recursion Pharmaceuticals worth $81.5K as of Q1 2026.
Prime Capital Investment Advisors sold 1,355 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.24K.
Recursion Pharmaceuticals made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #1011 holding.
Prime Capital Investment Advisors first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Prime Capital Investment Advisors's Recursion Pharmaceuticals position peaked at $154K in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.